🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT

Recruitingn/aAges 18 Years - anyAllZhiping Wang
NCT07589413 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis. The study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Pat

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18 years or older. 2. Suspected or histologically confirmed urothelial carcinoma of the bladder. 3. Scheduled to undergo TURBT. 4. Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis. 5. Availability of complete clinicopathological and perioperative data. 6. Ability to provide informed consent and comply with study follow-up. Exclusion Criteria: 1. Non-urothelial bladder malignancy confirmed by pathology. 2. History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. 3. Previous radical cystectomy or systemic antitumor therapy before enrollment. 4. Inadequate blood sample quality or insufficient DNA yield for mutation analysis. 5. Pregnancy or breastfeeding. 6. Serious uncontrolled intercurrent illness that may interfere with study participation, follow-up, or compliance, including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, severe psychiatric illness, or other conditions judged by the investigator to make participation unsuitable.
💊

What it tests

  • Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
📍

Where

1 site
The Second Hospital of Lanzhou University
Lanzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy